Synosia Therapeutics Announces Appointment of Chief Business Officer

Dec 13, 2007, 00:00 ET from Synosia Therapeutics

    SAN FRANCISCO, December 13 /PRNewswire/ -- Synosia Therapeutics today
 announced the appointment of Antony Blanc, Ph.D., as the company's new
 chief business officer, effective immediately.
     Dr Blanc, who will serve as head of Synosia's office in Basel,
 Switzerland, joins from Syngenta, where he created and led the
 biopharmaceuticals business unit. A molecular biologist by training and an
 experienced biotech entrepreneur, Dr. Blanc helped biotech and pharma
 clients with R&D, commercial and strategy issues as associate partner with
 the business consultants McKinsey & Company.
     "With a strong entrepreneurial flair in biotech and expertise in both
 science and business, Antony Blanc brings together the skills we need to
 lead our increasingly important presence in Switzerland," said Synosia
 Chief Executive Officer and President Dr. Ian Massey. "Our three
 pharmaceutical partners are based in Basel and this appointment will give
 us the leadership we need in Europe to meet our ambitious goals for 2008,
 including the start of four phase II trials."
     "Synosia has a broad clinical-stage portfolio with several advanced
 molecules, highly experienced leaders, a well-aligned and strong investor
 base and a grounding in both the US and in Switzerland. I look forward to
 building on this promising combination to create a leading CNS-focused
 specialty pharma company" said Blanc.
     Antony Blanc replaces Herve Girsault M.B.A., who will remain on
 Synosia's board of directors and continue to act as a key business advisor
 to the company.
     About Synosia Therapeutics
     Synosia Therapeutics develops and intends to commercialize innovative
 and clinically differentiated products for unmet medical needs in
 psychiatry and neurology. The privately-owned company is developing six
 clinical-stage compounds acquired through key partnerships with Novartis,
 Roche and Syngenta, including two marketed drugs that will be tested in new
 indications, extending their reach into new therapeutic areas with combined
 sales potential in excess of US$2.5 billion. Synosia has offices in Basel,
 Switzerland, and South San Francisco, CA.
     Synosia Therapeutics has raised US$32.5 million funding from Versant
 Ventures (Menlo Park, CA), Abingworth Management (London), 5AM Ventures
 (Menlo Park, CA) and Novo A/S (Copenhagen, Denmark). For more information,

SOURCE Synosia Therapeutics